Spotify back up after outage hits over 40,000 users
Former Dallas police officer Amber Guyger now eligible for parole six years after murder
‘It felt risqué:’ How a computer dating service launched in 1965 changed our love lives
Pakistanis protesting Hezbollah leader's killing clash with Karachi police
Iran's president denounces Israeli attacks on Tehran's regional allies
Israel used US-made bomb in attack on Hezbollah head, US senator says
China to cut existing mortgage rates by end-Oct, cities ease home-buying curbs
Packers QB Love available to play; CB Jaire Alexander out Sunday against Vikings
Alabama overtakes Texas for No. 1 and UNLV earns its 1st ranking in program history
‘LibraryTok’ is building school-age nostalgia on the internet. Fans can’t get enough
COPENHAGEN (Reuters) -Novo Nordisk said on Wednesday it would recognise an impairment loss of about 5.7 billion Danish crowns ($816.72 million) in the second quarter of 2024, after its CLARION-CKD phase 3 trial failed to meet its primary endpoint.
Novo has decided to stop its CLARION-CKD trial because it did not meet its primary endpoint of change in systolic blood pressure from baseline to week 12, the company said in a statement.
The impairment is related to ocedurenone, a drug for uncontrolled hypertension with potential application in cardiovascular and kidney disease, that Novo acquired from KBP Biosciences in October 2023, the Danish pharma giant said.
($1 = 6.9791 Danish crowns)
(Reporting by Louise Breusch Rasmussen, editing by Essi Lehto)
